A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies Than Any Individual Component
Overview
Authors
Affiliations
Unlabelled: The sequence diversity of human immunodeficiency virus type 1 (HIV-1) presents a formidable challenge to the generation of an HIV-1 vaccine. One strategy to address such sequence diversity and to improve the magnitude of neutralizing antibodies (NAbs) is to utilize multivalent mixtures of HIV-1 envelope (Env) immunogens. Here we report the generation and characterization of three novel, acute clade C HIV-1 Env gp140 trimers (459C, 405C, and 939C), each with unique antigenic properties. Among the single trimers tested, 459C elicited the most potent NAb responses in vaccinated guinea pigs. We evaluated the immunogenicity of various mixtures of clade C Env trimers and found that a quadrivalent cocktail of clade C trimers elicited a greater magnitude of NAbs against a panel of tier 1A and 1B viruses than any single clade C trimer alone, demonstrating that the mixture had an advantage over all individual components of the cocktail. These data suggest that vaccination with a mixture of clade C Env trimers represents a promising strategy to augment vaccine-elicited NAb responses.
Importance: It is currently not known how to generate potent NAbs to the diverse circulating HIV-1 Envs by vaccination. One strategy to address this diversity is to utilize mixtures of different soluble HIV-1 envelope proteins. In this study, we generated and characterized three distinct, novel, acute clade C soluble trimers. We vaccinated guinea pigs with single trimers as well as mixtures of trimers, and we found that a mixture of four trimers elicited a greater magnitude of NAbs than any single trimer within the mixture. The results of this study suggest that further development of Env trimer cocktails is warranted.
Prophylactic HIV-1 vaccine trials: past, present, and future.
Nkolola J, Barouch D Lancet HIV. 2023; 11(2):e117-e124.
PMID: 38141639 PMC: 11736820. DOI: 10.1016/S2352-3018(23)00264-3.
Vukovich M, Raju N, Kgagudi P, Manamela N, Abu-Shmais A, Gripenstraw K J Virol. 2023; 98(1):e0147823.
PMID: 38085509 PMC: 10804973. DOI: 10.1128/jvi.01478-23.
HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
Fries C, Chen J, Dennis M, Votaw N, Eudailey J, Watts B Sci Rep. 2021; 11(1):14494.
PMID: 34262096 PMC: 8280189. DOI: 10.1038/s41598-021-93702-x.
Strategies for inducing effective neutralizing antibody responses against HIV-1.
Moral-Sanchez I, Sliepen K Expert Rev Vaccines. 2019; 18(11):1127-1143.
PMID: 31791150 PMC: 6961309. DOI: 10.1080/14760584.2019.1690458.
Pharmacological plasticity-How do you hit a moving target?.
Parnham M, Geisslinger G Pharmacol Res Perspect. 2019; 7(6):e00532.
PMID: 31768257 PMC: 6868654. DOI: 10.1002/prp2.532.